Who are GIK and intensive insulin therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gik-and-intensive-insulin-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GIK and intensive insulin therapy — Competitive Intelligence Brief

GIK and intensive insulin therapy (GIK and intensive insulin therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Metabolic therapy / Insulin-based combination. Area: Cardiovascular.

phase 3 Metabolic therapy / Insulin-based combination Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

GIK and intensive insulin therapy (GIK and intensive insulin therapy) — University of Monastir. GIK (glucose-insulin-potassium) therapy combined with intensive insulin regimens improves myocardial metabolism and reduces ischemic injury by enhancing glucose uptake and oxidative metabolism in cardiac tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GIK and intensive insulin therapy TARGET	GIK and intensive insulin therapy	University of Monastir	phase 3	Metabolic therapy / Insulin-based combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Metabolic therapy / Insulin-based combination class)

University of Monastir · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GIK and intensive insulin therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gik-and-intensive-insulin-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab